This is an open-label, non-randomized Phase 1 dose escalation, followed by dose expansion, study to define the safety, tolerability, biomarker change and anti-tumor activity of IMU-935 in patients with mCRPC. Throughout the study, safety, anti-tumor activity, biomarkers and IMU-935 plasma concentrations will be evaluated at regular intervals as per schedule of assessments. Disease progression will be assessed as per standard medical practice.~The dose escalation and expansion parts of the study will have the same treatment duration with similarly structured treatment cycles.~The study will consist of the following periods:~Screening Period: Approximately 28 days~Treatment Phase:~Main treatment over 3 cycles of 28 days each, extended treatment as long as patient benefits
Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer (mCRPC).